174 related articles for article (PubMed ID: 31862185)
21. New prostate cancer prognostic grade group (PGG): Can multiparametric MRI (mpMRI) accurately separate patients with low-, intermediate-, and high-grade cancer?
Holtz JN; Silverman RK; Tay KJ; Browning JT; Huang J; Polascik TJ; Gupta RT
Abdom Radiol (NY); 2018 Mar; 43(3):702-712. PubMed ID: 28721479
[TBL] [Abstract][Full Text] [Related]
22. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature.
Fütterer JJ; Briganti A; De Visschere P; Emberton M; Giannarini G; Kirkham A; Taneja SS; Thoeny H; Villeirs G; Villers A
Eur Urol; 2015 Dec; 68(6):1045-53. PubMed ID: 25656808
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1.
Tamada T; Kido A; Yamamoto A; Takeuchi M; Miyaji Y; Moriya T; Sone T
J Magn Reson Imaging; 2021 Jan; 53(1):283-291. PubMed ID: 32614123
[TBL] [Abstract][Full Text] [Related]
24. Can
Chen M; Zhuang J; Fu Y; Guo S; Zang S; Ai S; Qiu X; Wang F; Guo H
J Urol; 2021 Apr; 205(4):1082-1089. PubMed ID: 33207140
[TBL] [Abstract][Full Text] [Related]
25. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW
BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
[TBL] [Abstract][Full Text] [Related]
26. Prostate Cancer: assessing the effects of androgen-deprivation therapy using quantitative diffusion-weighted and dynamic contrast-enhanced MRI.
Hötker AM; Mazaheri Y; Zheng J; Moskowitz CS; Berkowitz J; Lantos JE; Pei X; Zelefsky MJ; Hricak H; Akin O
Eur Radiol; 2015 Sep; 25(9):2665-72. PubMed ID: 25820537
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic accuracy of biparametric versus multiparametric prostate MRI: assessment of contrast benefit in clinical practice.
Zawaideh JP; Sala E; Shaida N; Koo B; Warren AY; Carmisciano L; Saeb-Parsy K; Gnanapragasam VJ; Kastner C; Barrett T
Eur Radiol; 2020 Jul; 30(7):4039-4049. PubMed ID: 32166495
[TBL] [Abstract][Full Text] [Related]
28. Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen.
Radtke JP; Schwab C; Wolf MB; Freitag MT; Alt CD; Kesch C; Popeneciu IV; Huettenbrink C; Gasch C; Klein T; Bonekamp D; Duensing S; Roth W; Schueler S; Stock C; Schlemmer HP; Roethke M; Hohenfellner M; Hadaschik BA
Eur Urol; 2016 Nov; 70(5):846-853. PubMed ID: 26810346
[TBL] [Abstract][Full Text] [Related]
29. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.
Touijer KA; Michaud L; Alvarez HAV; Gopalan A; Kossatz S; Gonen M; Beattie B; Sandler I; Lyaschenko S; Eastham JA; Scardino PT; Hricak H; Weber WA
Eur Urol Oncol; 2019 Mar; 2(2):166-173. PubMed ID: 31017093
[TBL] [Abstract][Full Text] [Related]
30. Quantitative contrast-enhanced perfusion kinetics in multiparametric MRI in differentiating prostate cancer from chronic prostatitis: results from a pilot study.
Sureka B; Elhence P; Khera PS; Choudhary GR; Pandey H; Garg PK; Yadav K; Goel A
Br J Radiol; 2019 Aug; 92(1100):20190181. PubMed ID: 31184934
[TBL] [Abstract][Full Text] [Related]
31. Prospective evaluation of the value of dynamic contrast enhanced (DCE) imaging for prostate cancer detection, with pathology correlation.
Al Salmi I; Menezes T; El-Khodary M; Monteiro S; Haider EA; Alabousi A
Can J Urol; 2020 Jun; 27(3):10220-10227. PubMed ID: 32544044
[TBL] [Abstract][Full Text] [Related]
32. Detection of Gleason 6 prostate cancer in patients with clinically significant prostate cancer on multiparametric magnetic resonance imaging.
Chaloupka M; Bischoff R; Pfitzinger P; Lellig E; Ledderose S; Buchner A; Schlenker B; Stief C; Clevert DA; Apfelbeck M
Clin Hemorheol Microcirc; 2019; 73(1):105-111. PubMed ID: 31561351
[TBL] [Abstract][Full Text] [Related]
33. Quantitative Prostate MRI Analysis Following Fluvastatin Therapy for Localized Prostate Cancer - A Pilot Study.
Avery A; Sussman M; Longo J; Menezes RJ; Hamilton RJ; der Kwast THV; Fleshner NE; Penn LZ; Ghai S
Can Assoc Radiol J; 2021 Nov; 72(4):750-758. PubMed ID: 33563030
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the accuracy of multiparametric MRI for predicting prostate cancer pathology and tumour staging in the real world: an multicentre study.
Kam J; Yuminaga Y; Krelle M; Gavin D; Koschel S; Aluwihare K; Sutherland T; Skinner S; Brennan J; Wong LM; Louie-Johnsun M
BJU Int; 2019 Aug; 124(2):297-301. PubMed ID: 30714285
[TBL] [Abstract][Full Text] [Related]
35. Biological effect of neoadjuvant androgen-deprivation therapy assessed on specimens from radical prostatectomy: a systematic review.
Antonelli A; Palumbo C; Veccia A; Grisanti S; Triggiani L; Zamboni S; Furlan M; Simeone C; Magrini S; Berruti A
Minerva Urol Nefrol; 2018 Aug; 70(4):370-379. PubMed ID: 29392925
[TBL] [Abstract][Full Text] [Related]
36. MRI features of the normal prostatic peripheral zone: the relationship between age and signal heterogeneity on T2WI, DWI, and DCE sequences.
Bura V; Caglic I; Snoj Z; Sushentsev N; Berghe AS; Priest AN; Barrett T
Eur Radiol; 2021 Jul; 31(7):4908-4917. PubMed ID: 33398421
[TBL] [Abstract][Full Text] [Related]
37. Spinal multiparametric MRI and DEXA changes over time in men with prostate cancer treated with androgen deprivation therapy: a potential imaging biomarker of treatment toxicity.
Martin J; Arm J; Smart J; Palazzi K; Capp A; Ainsworth P; Cowin G
Eur Radiol; 2017 Mar; 27(3):995-1003. PubMed ID: 27287481
[TBL] [Abstract][Full Text] [Related]
38. 18F-DCFBC Prostate-Specific Membrane Antigen-Targeted PET/CT Imaging in Localized Prostate Cancer: Correlation With Multiparametric MRI and Histopathology.
Turkbey B; Mena E; Lindenberg L; Adler S; Bednarova S; Berman R; Ton AT; McKinney Y; Eclarinal P; Hill C; Afari G; Bhattacharyya S; Mease RC; Merino MJ; Jacobs PM; Wood BJ; Pinto PA; Pomper MG; Choyke PL
Clin Nucl Med; 2017 Oct; 42(10):735-740. PubMed ID: 28806263
[TBL] [Abstract][Full Text] [Related]
39. Histopathological Features of MRI-Invisible Regions of Prostate Cancer Lesions.
van Houdt PJ; Ghobadi G; Schoots IG; Heijmink SWTPJ; de Jong J; van der Poel HG; Pos FJ; Rylander S; Bentzen L; Haustermans K; van der Heide UA
J Magn Reson Imaging; 2020 Apr; 51(4):1235-1246. PubMed ID: 31588646
[TBL] [Abstract][Full Text] [Related]
40. Performance of prostate multiparametric MRI for prediction of prostate cancer extra-prostatic extension according to NCCN risk categories: implication for surgical planning.
Falagario UG; Jambor I; Ratnani P; Martini A; Treacy PJ; Wajswol E; Lantz A; Papastefanou G; Weil R; Phillip D; Lewis S; Haines K; Cormio L; Carrieri G; Kyprianou N; Wiklund P; Tewari AK
Minerva Urol Nefrol; 2020 Dec; 72(6):746-754. PubMed ID: 32182231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
